Literature DB >> 7484822

The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction.

N B Høst1, L T Jensen, P M Bendixen, S E Jensen, O G Koldkjaer, E E Simonsen.   

Abstract

The aim of the study was to examine sequential changes in serum levels of the aminoterminal propeptide of type III procollagen (S-PIIINP) after acute myocardial infarction (AMI), and to assess the value of S-PIIINP as a predictor of outcome. The study group comprised 74 patients with AMI, and 24 patients in whom AMI was suspected but disproved. S-PIIINP changed characteristically after AMI, and in patients not receiving thrombolytic therapy or having cardiogenic shock, the changes correlated to peak enzyme values (r = 0.4, p < or = 0.03). S-PIIINP was higher at days 0 to 2 in nonsurviving AMI patients than in survivors (p < 0.05). With use of either the upper quartile for S-PIIINP at day 0 for nonsurviving AMI patients or the mean value of S-PIIINP in a normal population plus 2 SDs as a cutoff, the predictive value of a negative test ranged from 0.79 to 0.87 at days 0 to 2, and the predictive value of a positive test ranged from 0.39 to 0.67. Thus, S-PIIINP on admission and for the following few days after AMI is higher in patients with poor outcome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7484822     DOI: 10.1016/s0002-9149(99)80251-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

1.  Time course of plasma markers of collagen turnover in patients with acute myocardial infarction.

Authors:  A D McGavigan; J Moncrieff; M M Lindsay; P R Maxwell; F G Dunn
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

2.  Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction.

Authors:  Jirmar Radovan; Pelouch Vaclav; Widimsky Petr; Capek Jan; Andel Michal; Prusa Richard; Pechova Martina
Journal:  Mol Cell Biochem       Date:  2006-08-24       Impact factor: 3.396

Review 3.  Spironolactone in congestive heart failure.

Authors:  J E Soberman; K T Weber
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 4.  Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure.

Authors:  Faiez Zannad; Anca Radauceanu
Journal:  Heart Fail Rev       Date:  2005-01       Impact factor: 4.214

Review 5.  Biomarkers: optimizing treatment guidance in heart failure.

Authors:  Michael Böhm; Adriaan A Voors; Jean-Marie Ketelslegers; Stephan H Schirmer; Eva Turgonyi; Peter Bramlage; Faiez Zannad
Journal:  Clin Res Cardiol       Date:  2011-07-16       Impact factor: 5.460

6.  Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the community.

Authors:  Thomas J Wang; Martin G Larson; Emelia J Benjamin; Deborah A Siwik; Radwan Safa; Chao-Yu Guo; Diane Corey; Johan Sundstrom; Douglas B Sawyer; Wilson S Colucci; Ramachandran S Vasan
Journal:  Am Heart J       Date:  2007-08       Impact factor: 4.749

Review 7.  Cardiac biomarkers in children with congenital heart disease.

Authors:  Masaya Sugimoto; Seiko Kuwata; Clara Kurishima; Jeong Hye Kim; Yoich Iwamoto; Hideaki Senzaki
Journal:  World J Pediatr       Date:  2015-10-11       Impact factor: 2.764

Review 8.  The myocardial matrix and the development and progression of ventricular remodeling.

Authors:  J D Sackner-Bernstein
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 3.955

9.  Levels of Circulating MMCN-151, a Degradation Product of Mimecan, Reflect Pathological Extracellular Matrix Remodeling in Apolipoprotein E Knockout Mice.

Authors:  N Barascuk; E Vassiliadis; Q Zheng; Y Wang; W Wang; L Larsen; L M Rasmussen; M A Karsdal
Journal:  Biomark Insights       Date:  2011-09-22

10.  Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease.

Authors:  Dong Fan; Abhijit Takawale; Jiwon Lee; Zamaneh Kassiri
Journal:  Fibrogenesis Tissue Repair       Date:  2012-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.